



Rotational Thromboelastometry or Conventional Coagulation Tests in Liver Transplantation: Comparing Blood Loss, Transfusions, and Cost

Laura Smart,* Khalid Mumtaz,** Danielle Scharpf,*** Nicole O'Bleness Gray,**
Daniel Traetow,*** Sylvester Black,**** Anthony J. Michaels,** Elmahdi Elkhammas,**** Robert Kirkpatrick,** A. James Hanje**

* Division of Gastroenterology, Hepatology, and Nutrition, University of Louisville, Louisville, KY, USA.

** Division of Gastroenterology, Hepatology, and Nutrition, The Ohio State University Wexner Medical Center, Columbus, OH, USA.

*** Department of Anesthesiology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.

**** Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, USA.

ABSTRACT

Introduction. Orthotopic liver transplantation (OLT) can be associated with significant bleeding requiring multiple blood product transfusions. Rotational thromboelastometry (ROTEM) is a point-of-care device that has been used to monitor coagulation during OLT. Whether it reduces blood loss/transfusions during OLT remains controversial. **Materials and methods.** We aim to compare ROTEM with conventional coagulation tests (aPTT, PT, INR, platelet count, fibrinogen) to guide transfusion of platelets, cryoprecipitate, and fresh frozen plasma (FFP) during OLT over 3 years. Thirty-four patients who had transfusions guided by ROTEM were compared to 34 controls who received transfusions guided by conventional coagulation tests (CCT). Intraoperative blood loss, type/amount of blood products transfused, and direct costs were compared between the two groups. **Results.** The ROTEM group had significantly less intra-operative blood loss (2.0 vs. 3.0 L, $p = 0.04$) and fresh frozen plasma (FFP) transfusion (4 units vs. 6.5 units, $p = 0.015$) compared to the CCT group (2.0L vs. 3.0L, $p = 0.04$). However, total number of patients transfused cryoprecipitate was increased in ROTEM ($n = 25; 73\%$) as compared to CCT ($n = 19; 56\%$), $p = 0.033$. The direct cost of blood products plus testing was reduced in the ROTEM group (\$113,142.89 vs. \$127,814.77). **Conclusion.** In conclusion implementation of a ROTEM-guided transfusion algorithm resulted in a reduction in intra-operative blood loss, FFP transfusion and a decrease in direct cost during OLT. ROTEM is a useful and safe point of care device in OLT setting.

Key words. ROTEM. Transplant. Transfusion. Blood products. Fresh frozen plasma.

INTRODUCTION

Orthotopic liver transplantation (OLT) can be associated with significant bleeding requiring transfusion of multiple blood products, especially in patients with advanced liver disease. Conventional coagulation tests (CCT) such as prothrombin time (PT), international normalized ratio (INR), activated partial thromboplastin time (aPTT), fibrinogen, and platelet count are used to guide transfusions in liver transplant setting. However, these tests are limited by their inability to assess clot strength and the functionality of fibrinogen or hyperfibrinolysis that may be present. Rotational thromboelastometry (ROTEM) monitors viscoelastic properties of whole blood

clot formation and degradation, allowing for a comprehensive view of the entire coagulation cascade. Rotational thromboelastometry (ROTEM) is a point-of-care device that has been successfully used to monitor coagulation on whole blood samples during cardiac surgery and trauma.¹⁻⁴ Literature on its use in the setting of OLT is growing.⁵⁻⁷

In patients undergoing liver transplantation, ROTEM has been shown to quickly and correctly predict hypofibrinogenemia, thrombocytopenia, and decreased clot firmness.⁸ Furthermore, researchers suggest that while PT and INR are used as prognostic indicators and to guide blood product management, these tests are poor predictors of bleeding risk in liver disease.⁹ This challenges the current practice of correcting an abnormal INR with fresh

frozen plasma (FFP) prior to invasive procedures, such as OLT. Overall bleeding risk cannot be accurately predicted by INR, as it measures only one of the many components of coagulation and clot stability. Transfusion of pRBCs, FFP, and platelets has been shown to be associated with increased morbidity and mortality in transplantation as well as worse graft survival.²

In addition to increased rates of infection and prolonged stays in intensive care units,³ increased transfusion rates can be very costly to both the patient and hospital. Toner, *et al.* found in their cross-sectional randomized study of 213 US centers that the mean cost for one unit of pRBCs was $\$210.74 \pm 37.9$ and the mean charge to the patient was $\$346.63 \pm 135$.¹⁰

Few studies have compared the cost of blood products and coagulation factors before and after the implementation of a ROTEM protocol. Gorlinger, *et al.* found an overall savings of 36% after implementation of ROTEM in visceral and liver transplantation surgery in Germany. Reduction in the cost of blood products with increase in cost of coagulation factors resulted in a decrease in overall cost.⁷ Cost reduction with the use of ROTEM has also been reported in cardiac and neurosurgery.^{11,12}

Our primary aim in this study was to assess the impact of a ROTEM-guided transfusion protocol on intra-operative blood loss during OLT. We also assessed intra-operative transfusion requirements (total and for each blood component) and the direct cost of ROTEM based & conventional coagulation tests and blood products.

MATERIALS AND METHODS

Sixty-eight consecutive patients who underwent OLT from 2012 to 2014 at The Ohio State University Wexner Medical Center (OSUWMC) were included in this study. Data of thirty-four patients who received ROTEM guided transfusions after July 1, 2013 was collected prospectively and compared to the prior thirty-four patients who received transfusions based on conventional coagulation tests (PT, aPTT, INR, hemoglobin, platelets, and fibrinogen). There was no randomization and standardized anesthesia and surgical techniques were used; surgeries were performed by three equally experienced surgeons. Hemodynamic monitoring, antibiotics and immunosuppressive medications were also standardized in the two groups. All patients age 18 years or older who received a liver graft from a deceased donor and underwent OLT were included. The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki reflected in an exemption granted by our hospital Institutional Review Board.

Intra-operative blood product use (type and amount) as well as coagulation test results pre- and post-OLT were collected on all patients. Blood products given during

OLT were pRBCs, FFP, cryoprecipitate, platelets, and salvaged blood. The amount of salvaged blood, which was recorded in milliliters, was converted to units by dividing the volume by 200 and then multiplying by 55%. This was based on one unit of pRBC having a red cell mass of 200 mL and salvaged blood having an approximate hematocrit of 55%, which has been previously reported.¹³ Salvaged blood was converted to units so the total amount of blood transfused could be calculated in units. Intra-operative blood loss was estimated and recorded by the anesthesia provider. Data was extracted from charts in the electronic medical record, de-identified, and used to construct a database of OLT recipients with information on risk factors, pre-operative, and post-operative testing.

Blood products were transfused in the ROTEM group based on the algorithm in Figure 1. Four assays (EXTEM, INTEM, FIBTEM, and HEPTTEM) were completed for each patient in the ROTEM group after optimizing calcium, temperature, pH, and hemoglobin. In EXTEM, coagulation is activated by a small amount of tissue thromboplastin and allows for assessment of factors VII, X, V, II, I, platelets, and fibrinolysis. In INTEM, coagulation is activated via the contact phase and is sensitive for factor deficiencies of the intrinsic coagulation cascade (factors XII, XI, IX, VIII, X, V, II, I) and for the presence of heparin in the sample. In FIBTEM, coagulation is activated as in EXTEM but cytochalasin D is added so platelets are blocked. The resulting clot is therefore only dependent on fibrin formation and polymerization so fibrin deficiencies are detected. In HEPTTEM, coagulation is activated as in INTEM but heparinase in the reagent degrades heparin present in the sample so abnormalities due only to heparin are detected. Based on these assays, FFP, platelets, and/or cryoprecipitate were transfused according to our algorithm in Figure 1. Protamine or aminocaproic acid were also given based on the ROTEM results for residual heparin effect or primary fibrinolysis, respectively. Unfortunately, number of patients given either of these was not recorded in this study. Prior studies have shown that 20-36% of patients undergoing OLT develop hyperfibrinolysis and aminocaproic acid is a treatment.^{6,14,15} Blood products including platelets and FFPs were transfused in the CCT group per the protocol in Figure 2, and fibrinogen was transfused only if the patient was still bleeding or fibrinogen was still low.

During OLT temperature was maintained above 36 °C, and pH was kept above 7.3. Calcium was infused to keep the ionized calcium level above 4.5 g/dL and hemoglobin was maintained above 8 g/dL. ROTEM tests (EXTEM, INTEM, FIBTEM, and HEPTTEM) were only performed for patients in the ROTEM group according to the manufacturer's instructions by anesthesia providers. Coagulation tests for all patients and ROTEM tests for patients in the ROTEM group




Figure 1. Ohio State University Liver Transplant Transfusion Algorithm (ROTEM).




Figure 2. Ohio State University Liver Transplant Transfusion Algorithm (Conventional Coagulation Tests).

were performed at baseline, at the an-hepatic phase, at neohepatic reperfusion, prior to transfer to the intensive care unit, and at any other time deemed necessary by the clinical judgement of the anesthesia provider or surgeon.

The direct cost per unit of each type of blood product was obtained from OSUWMC’s Transfusion Services, and total cost of products was then calculated. The cost of conventional coagulation tests was obtained from OSUWMC’s laboratory services, and the cost of ROTEM reagents was obtained from Tem Systems, Inc. The cost of operating the ROTEM (manpower) is equivalent to performing the laboratory tests so this cost was not included.

The total costs for testing were then calculated based on running four ROTEMs or four sets of conventional coagulation tests per surgery, which is the average number of tests performed during a liver transplant at OSUWMC.

Our sample size of sixty-eight patients was based on a pilot project at OSUWMC that evaluated a total of sixteen patients. The amount of blood products transfused and intraoperative blood loss were studied in the pilot project, with a trend toward decreased total blood product use (10.1 units *vs.* 20.5 units) and blood loss (2.0 units *vs.* 3.0 units) found in the ROTEM group. With the χ^2 test and a 2-sided α value of 0.05 as the significance criterion, a sam-

ple size of thirty-four patients per group was calculated to provide 80% power to demonstrate the influence of ROTEM on decreasing intraoperative blood loss during OLT.

Baseline patient characteristics as well as pre- and post-procedure laboratory values were compared between patients transfused using the ROTEM algorithm and CCT. Fisher exact tests were used to test for significant differences between the ROTEM and CCT groups with discrete variables such as race and gender. With continuous variables that were approximately normally distributed (BMI, MELD, and age), two-sample t-tests were used to test for significant differences between groups. Due to the non-normality of all laboratory values and ICU length of stay, nonparametric Wilcoxon rank-sum tests were used to test for significance.

Blood product usage and blood loss during OLT comparing ROTEM *vs.* CCT guided transfusion were also analyzed. Due to the non-normality of the data, nonparametric Wilcoxon rank-sum tests were used to test for significant differences between the two groups in terms of the use of the 5 different blood products and blood loss. The sum of pRBCs, FFP, platelets, cryoprecipitate, and salvaged blood in units was used as an indicator of total blood product use. Results are expressed as medians and interquartile ranges. A two-tailed P value < 0.05 was considered significant.

RESULTS

From May 2012 to December 2014, 68 consecutive patients who underwent OLT were included: 34 patients each in the ROTEM group and the CCT group. Patient characteristics were comparable between groups as shown in table 1. The reported MELD scores are calculated from laboratory data and exclude any exception points. Laboratory values prior to and immediately post OLT are presented in table 2. No significant differences were observed among the baseline laboratory values between groups. After surgery, both the INR and platelet count were significantly higher in the ROTEM group (2.0 *vs.* 1.7, $p = 0.01$ and 98000 *vs.* 63000, $p = 0.002$, respectively).

The number of patients transfused each blood product is presented in table 3, along with the subsequent amount of each product transfused. Both individual blood products and the total of all blood products were compared between groups. Patients in the ROTEM group received significantly less FFP (4 units *vs.* 6.5 units, $p = 0.02$) but more cryoprecipitate (2 units *vs.* 1 units, $p = 0.04$). The total amount of blood products transfused was less in the ROTEM group but did not reach statistical significance (14.5 units *vs.* 17 units, $p = 0.11$). The amount of blood transfused (pRBCs + salvaged blood) was also less in the ROTEM group (5.5 units *vs.* 8 units, $p = 0.07$). Intraopera-

Table 1. Patient characteristics.

	ROTEM (n = 34)	CCT (n = 34)
Age (years)*	56 (50-59)	54 (48-59)
Male sex (%)	62	65
BMI (kg/m ²)*	30 (24-34)	29 (27-34)
Race		
White (%)	91	91
Non-White (%)	9	9
Indication for OLT		
Hepatitis C virus cirrhosis	11	13
Non-alcoholic Steatohepatitis	5	6
Alcoholic cirrhosis	5	4
Hepatitis C virus/Alcoholic cirrhosis	2	5
Alpha-1 Anti-trypsin cirrhosis	3	0
Cryptogenic cirrhosis	0	3
Hepatitis B virus cirrhosis	1	2
Auto-immune hepatitis	2	0
Primary sclerosing cholangitis	1	0
Acute liver failure	2	1
Primary biliary cirrhosis	1	0
Model for end-stage liver disease score*	30 (23-33)	25 (18-30)
Hepatocellular carcinoma (n)	13	10
Portal vein thrombosis (n)	4	2
Hypercoagulable state (n)	0	2
ICU Length of stay (days)*	3 (2-3)	3 (1-3)
30-day Mortality (n)	1	1
60-day Mortality (n)	1	1

No difference was statistically significant. * The data is expressed as medians and interquartile ranges.

Table 2. Laboratory values pre- and post-OLT in two intervention groups.

	Pre-OLT			Post-OLT		
	ROTEM	CCT	P-value	ROTEM	CCT	P-value
Hemoglobin (g/dL)	9.9 (8.6-12.6)	10.5 (8.9-12.1)	0.7859	9.4 (8.4-10.8)	9.2 (7.9-10.4)	0.7578
Platelets (K/uL)	73 (54-104)	66 (41-94)	0.3204	98 (69-114)	63 (49-87)	0.0016
Fibrinogen (mg/dL)	166 (122-239)	212 (134-241)	0.3469	220 (168-234)	193 (163-235)	0.4433
INR	1.8 (1.4-2.8)	1.7 (1.4-2.4)	0.4645	2.0 (1.7-2.3)	1.7 (1.5-2.0)	0.0119
Total Bilirubin (mg/dL)	5.1 (1.6-11.8)	3.9 (2.1-11.8)	0.9658	N/A	N/A	N/A
Creatinine (mg/dL)	0.99 (0.79-1.8)	1.05 (0.83-1.4)	0.9024	N/A	N/A	N/A

The data is expressed as medians and interquartile ranges.

Table 3. Number of patients and quantities of transfusions of blood products during OLT.

Intraoperative transfusions	ROTEM		CCT		P-value
	Patients transfused	Quantities transfused	Patients transfused	Quantities transfused	
pRBC	28 (82)	4 (2-8)	33 (97)	5 (4-12)	0.1352
FFP28 (82)	4 (2-7)	30 (88)	6.5 (4-14)		0.0152
Platelets	27 (79)	2 (1-4)	24 (71)	2 (0-4)	0.7040
Cryoprecipitate	25 (73)	2 (0-3)	19 (56)	1 (0-2)	0.0339
Cell Saver	19 (56)	1 (0-3)	25 (74)	2 (0-6)	0.1211
Total Product Use	N/A	14.5 (8-27)	N/A	17 (10-39)	0.1013
pRBC + Cell Saver	N/A	5.5 (2-11)	N/A	8 (4-16)	0.0661

Blood Loss in OR (mL)	ROTEM		CCT		P-value
	2000	(1500-3375)	3000	(2000-7750)	
					0.0375

All patients were included in the data set, regardless of transfusion status. The data is expressed as numbers and percentages or as medians and interquartile ranges. All products listed are in units, including combinations and totals. The number of patients transfused for each category was not statistically significant between the ROTEM/Conventional cohorts. P-values are for quantities transfused.

tive blood loss was significantly lower in in the ROTEM group (2.0 vs. 3.0 L, $p = 0.04$).

Median ICU length of stay, 30- and 60- day mortality were the same in both groups. Two patients died in each group; causes of death were liver failure due to primary graft non-function in the ROTEM and cardiac arrhythmia in the CCT group (Table 1).

Direct cost results for blood products and testing are presented in tables 4 and 5. The total direct cost of blood products was less in the ROTEM group (\$103,786.09 vs \$123,067.01), table 4. Head to head cost of ROTEM laboratory testing was higher than CCT (\$9,356.80 vs. \$4,747.76), table 5. However, the overall cost of blood products plus laboratory testing was less in the ROTEM group (\$113, 142.89 vs. \$127,814.77).

DISCUSSION

In our comparison of ROTEM with conventional coagulation testing in liver transplant recipients, we found that

the implementation of a ROTEM-based transfusion protocol during OLT led to significantly less intraoperative blood loss. We also noticed a decrease in transfusion of FFP and increase in cryoprecipitate, in the ROTEM group, as compared to the CCT group. Moreover, a decrease in total direct cost of blood products plus laboratory tests was observed in the ROTEM group.

Reduction in blood loss with the help of ROTEM is of clinical importance. Though intraoperative blood loss can be a somewhat subjective metric as it is estimated by the surgeon/anesthesiologist, the simultaneous decrease in salvaged blood use in the ROTEM group is supportive of these results. A Cochrane review by Gurusamy, *et al.*¹⁶ also showed reduced blood loss and blood transfusion requirements with the use of thromboelastography in two included trials. Other studies do show reduction in blood transfusion but none is able to demonstrate reduced blood loss.^{5-7,17}

Reduction in FFP transfusion and increase in cryoprecipitate in the ROTEM group in our study is in con-

Table 4. Direct cost of blood products during OLT.

Intraoperative transfusions	Cost/unit (USD)	ROTEM Cost (USD)	CCT Cost (USD)
pRBCs	206.28	33,829.92	46,000.44
FFP	47.31	9,130.83	17,646.63
Platelets	489.97	39,687.57	41,647.45
Cryoprecipitate	335.33	21,137.77	17,772.49
Total		103,786.09	123,067.01

All patients were included in the data set, regardless of transfusion status. USD: United States Dollar.

Table 5. Cost comparison of ROTEM and Conventional Coagulation Tests.

ROTEM		CCT	
Test	Cost (USD)	Test	Cost (USD)
INTEM	12.01	PT/INR	6.73
EXTEM	12.01	PTT	8.54
FIBTEM	24.92	Fibrinogen	9.37
HEPTEM	19.86	CBC	10.27
Total	68.8	Total	34.91
Total (34 patients)	9,356.80	Total (34 patients)	4,747.76

Costs were obtained from OSUWMCs laboratory and from Tem systems, Inc. USD: United States Dollar.

trast to the recent study by Roulet, *et al.*,⁶ which did not find any difference in these outcomes with implementation of their ROTEM-based transfusion algorithm. However, early study of ROTEM by Roulet, *et al.* resulted in an increased amount of fibrinogen transfusion.¹⁸ Based on the lessons learned from early protocol they changed their transfusion policy resulting in minimized FFP use in their recently published study.⁶ Authors of this study have also admitted to their change in practice evolved between 2008-2009 and 2012, and resulting low transfusion rate that was probably difficult to lower more, particularly for FFP.

Several previous studies have shown a decrease in transfusion of FFP with some reporting a decrease in overall blood product use with the implementation of a ROTEM-guided transfusion protocol.^{5-7,17} Our results build on these prior studies also demonstrated a significant decrease in FFP and increase in cryoprecipitate use. Prior to implementation of the ROTEM-based transfusion protocol at our institution, FFPs were preferentially given to correct coagulopathy. However, once the ROTEM-based algorithm was applied, cryoprecipitate was instead transfused more due to ROTEM's better assessment of coagulation. In a large retrospective, multicenter study, Gorlinger, *et al.* found a decrease in transfusion of FFP, pRBCs, and platelet concentrate with an increase in fibrinogen concentrate and Prothrombin Complex Con-

centrate (PCC) in visceral surgery and OLT after implementation of a ROTEM-based transfusion protocol.⁷ Some blood products such as fibrinogen and PCC are not available for use in USA, therefore we used cryoprecipitate. Hence, our findings of increased use of cryoprecipitate need to be correlated with European centers' increased fibrinogen use.

While many studies have looked at the effect of a ROTEM-based transfusion algorithm on blood product use, few have compared the cost of blood products and coagulation factors before and after the implementation of such a protocol. Despite the increased cost of laboratory testing, use of the ROTEM-based transfusion algorithm at our study center decreased the direct costs by 11.5%. Similarly, Gorlinger, *et al.* found a savings of 36% when comparing direct costs of blood products and coagulation factor concentrates after implementation of a ROTEM-based transfusion protocol in visceral surgery and OLT in Germany.⁷ Similarly, Spalding, *et al.* found a savings of 44% after implementation of ROTEM-based transfusion protocol in cardiac surgery.¹¹ Previously reported studies have not mentioned the cost of ROTEM testing, rather they reported the cost of blood products and coagulation factors. Despite the fact that the cost of ROTEM testing is almost twice the cost of conventional coagulation tests in our study, we felt these costs were important to elucidate. This finding suggests that it is not the cost of ROTEM

testing but the reduction in cost of blood products linked to reduction in direct cost. Future studies are warranted to address total direct^{19,20} and indirect hospital costs between groups and we speculate there would be a greater cost savings in the ROTEM group.

A key distinction of this study is the subjects we included in our analysis. Previous studies have only involved patients receiving transfusion, with their amount of blood products transfused included in the analyses.^{6,7} Our study included all patients, regardless of transfusion status, as we felt this provided a more comprehensive assessment of intraoperative transfusion requirements. Our study also included sicker patients with liver disease as reflected by a higher MELD score of 30 and 25 in ROTEM and CCT groups, respectively.

One of the major limitations of our study is that we compared the ROTEM group with a retrospective cohort. The ROTEM group may have had a better perioperative experience from the surgeons/anesthesiologists perspective and may not be absolutely comparable to the experience in the CCT group. This is an important bias in this analysis, however, the two groups of patients were consecutive and our team of surgeons, anesthesiologists and hepatologists was unchanged during that time period. The majority of studies have used a similar study design, and no randomized trial is available in this area to our knowledge.

The implementation of a ROTEM-based transfusion protocol reduced intraoperative blood loss and FFP use during OLT. Furthermore, the reduction in total direct costs of blood products plus coagulation tests after implementation of the ROTEM-based transfusion protocol readily supports its safety and utility during OLT. Further studies are needed in larger cohorts to confirm the efficacy of ROTEM in OLT and assess its potential use in patients with acute liver failure or cirrhosis requiring transfusions.

ABBREVIATIONS

- **aPTT**: activated partial thromboplastin time.
- **CCT**: conventional coagulation tests.
- **BMI**: body mass index.
- **FFP**: fresh frozen plasma.
- **ICU**: intensive care unit.
- **INR**: international normalized ratio.
- **LT**: orthotopic liver transplantation.
- **OSUWMC**: The Ohio State University Wexner Medical Center.
- **pRBCs**: packed red blood cells.
- **PT**: prothrombin time.
- **ROTEM**: rotational thromboelastometry.
- **SCT**: Standard coagulation tests.

FINANCIAL SUPPORT

No grants or other financial support was received by any participating authors of this manuscript.

CONFLICT OF INTEREST

All authors declare no conflicts of interest.

ACKNOWLEDGEMENT

None.

All authors participated in data collection, editing of the manuscript and contributed to the final version of this article.

REFERENCES

1. Weber CF, Gurlinger K, Meininger D, Herrmann E, Bingold T, Moritz A, Cohn LH, et al. Point-of-care testing: a prospective, randomized clinical trial of efficacy in coagulopathic cardiac surgery patients. *Anesthesiology* 2012; 117: 531-47.
2. Cacciarelli TV, Keeffe EB, Moore DH, Burns W, Busque S, Concepcion W, So SK, et al. Effect of intraoperative blood transfusion on patient outcome in hepatic transplantation. *Arch Surg* 1999; 134: 25-9.
3. More E, Jennings L, Gonwa TA, Holman MJ, Gibbs J, Solomon H, Goldstein RM, et al. The impact of operative bleeding on outcome in transplantation of the liver. *Surg Gynecol Obstet* 1993; 176: 219.
4. Görlinger K, Dirkmann D, Hanke AA, Kamler M, Kottenberg E, Thielmann M, Jakob H, et al. First-line therapy with coagulation factor concentrates combined with point-of-care coagulation testing is associated with decreased allogeneic blood transfusion in cardiovascular surgery: a retrospective, single-center cohort study. *Anesthesiology* 2011; 115: 1179-91.
5. Wang SC, Shieh JF, Chang KY, Chu YC, Liu CS, Long CC, Chan KH, et al. Thromboelastography-guided transfusion decreases intraoperative blood transfusion during orthotopic liver transplantation: randomized clinical trial. *Transplant Proc* 2010; 42: 2590-3.
6. Rouillet S, Freyburger G, Cruc M, Quinart A, Stecken L, Audy M, Chiche L, et al. Management of bleeding and transfusion during liver transplantation before and after the introduction of a rotational thromboelastometry-based algorithm. *Liver Transplantation* 2015; 21: 169-79.
7. Gurlinger K, Fries D, Dirkmann D, Weber CF, Hanke AA, Schochl H. Reduction of fresh frozen plasma requirements by perioperative point-of-care coagulation management with early calculated goal-directed therapy. *Transfus Med Hemother* 2012; 39: 104-13.
8. Song JG, Jeong SM, Jun IG, Lee HM, Hwang GS. Five-minute parameter of thromboelastometry is sufficient to detect thrombocytopenia and hypofibrinogenaemia in patients undergoing liver transplantation. *Br J Anaesth* 2014; 112: 290-7.
9. Montalto P, Vlachoglanrakos J, Cox DJ, Pastacaldi S, Patch D, Burroughs AK. Bacterial infection in cirrhosis impairs coagulation by a heparin effect: a prospective study. *J Hepatol* 2002; 37: 463-70.

10. Toner RW, Pizzi L, Leas B, Ballas SK, Quigley A, Goldfarb NI. Cost to hospitals of acquiring and processing blood in the US: A survey of hospital-based blood banks and transfusion services. *Appl Health Econ Health Policy* 2011; 9: 29-37.
11. Spalding G, Harturmpf M, Sierig T, Oesberg N, Kirschke CG, Albes JM. Cost reduction of perioperative coagulation management in cardiac surgery: value of bedside thromboelastography. *Eur J Cardiothorac Surg* 2007; 31: 1052-7.
12. Haas T, Goobie S, Spielmann N, Weiss M, Schmugge M. Improvements in patient blood management for pediatric craniostoma surgery using a ROTEM-assisted strategy – feasibility and costs. *Paediatr Anaesth* 2014; 24: 774-80.
13. Brecher ME, Monk T, Goodnough LT. A standardized method for calculating blood loss. *Transfusion* 1997; 37: 1070-4.
14. Abuelkasem E, Lu S, Tanaka K, Planinsic R, Sakai T. Comparison between thrombelastography and thromboelastometry in hyperfibrinolysis detection during adult liver transplantation. *Br J Anaesth* 2016; 116: 507-12.
15. Mangus RS, Kinsella SB, Fridell JA, Kubal CA, Lahsaei P, Mark LO, Tector AJ. Aminocaproic Acid (Amicar) as an Alternative to Aprotinin (Trasylol) in Liver Transplantation. *Transplantation Proceedings* 2014; 46: 1393-9.
16. Gurusamy KS, Pissanou T, Pikhart H, Vaughan J, Burroughs AK, Davidson BR. Methods to decrease blood loss and transfusion requirements for liver transplantation. *Cochrane Database Syst Rev* 2011;12:CD009052.
17. Noval-Padillo JA, Leon-Justel A, Mellado-Miras P, Porrás-Lopez F, Villegas-Duque D, Gomez-Bravo MA, Guerrero JM. Introduction of fibrinogen in the treatment of hemostatic disorders during orthotopic liver transplantation: implications in the use of allogenic blood. *Transplant Proc* 2010; 42: 2973-4.
18. Rouillet S, Pillot J, Freyburger G, Biais M, Quinart A, Rault A, Revel P, et al. Rotation thromboelastometry detects thrombocytopenia and hypofibrinogenaemia during orthotopic liver transplantation. *Br J Anaesth* 2010; 104: 422-8.
19. Glenngård AH, Persson U, Söderman C. Costs associated with blood transfusions in Sweden – the societal cost of autologous, allogeneic and perioperative RBC transfusion. *Transfus Med* 2005; 15: 295-306.
20. Shander A, Hofmann A, Ozawa S, Theusinger OM, Gombotz H, Spahn DR. Activity-based costs of blood transfusions in surgical patients at four hospitals. *Transfusion* 2010; 50: 753-65.

Correspondence and reprint request:

Khalid Mumtaz, M.D., MSc.

Division of Gastroenterology, Hepatology and Nutrition
Ohio State University, Wexner Medical Center
395 W. 12th Ave., Faculty Office Tower
Columbus, OH 43210-1240

Phone: (614) 293-6255; Fax: (614) 293-8516

E-mail: Khalid.mumtaz@osumc.edu